Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
The analyst price target for LENSAR has been set at $10, compared with an unchanged fair value estimate of $8.50 in the updated model. Bullish commentary links this $10 target to expectations that profitability and the ALLY System's adoption can support that higher level, while more cautious views highlight execution and growth risks around the same figure. As you read on, you will see how these differing views are shaping the evolving story around LENSAR and what to watch next.
Wall Street's queuing for one rocket.While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page .
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
BTIG raised its rating on LENSAR to Buy from Neutral and set a US$10 price target, aligning with the upper end of current analyst views around the stock.
-
BTIG points to the ALLY System's prior adoption before the proposed Alcon acquisition, and views the post deal selloff as giving investors a second chance to reassess the story at a lower valuation.
-
Recent commentary from BTIG and Lake Street reflects renewed interest in LENSAR as analysts rework models around profitability potential tied to the ALLY platform.
🐻 Bearish Takeaways
-
Even with rating upgrades, analysts warn that the same factors that drove the post acquisition selloff, including execution and growth uncertainty, remain key risks to the US$10 target.
-
Cautious investors point to the gap between the US$8.50 fair value estimate and higher targets such as BTIG's US$10, reading that spread as a reminder that delivery on adoption and profitability goals is not assured.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 2 risks for LENSAR. See which could impact your investment.
What's in the News
-
Alcon Research, LLC cancelled its planned acquisition of LENSAR on March 16, 2025, which had valued the company at approximately US$180m, or US$14 per share in cash plus a contingent value right of up to US$2.75 per share.
-
The terminated deal followed prior approvals, including votes in favor by 15,983,846 holders and board approvals, and had been expected to close in the first half of 2026 subject to FTC regulatory clearance.
-
On April 10, 2026, Chief Financial Officer Thomas R. Staab, II notified LENSAR of his intention to resign effective May 8, 2026, with the company stating his decision was not due to any disagreement over operations, policies, or practices.
-
On May 25, 2026, LENSAR's Board appointed Michael A. Rossi as Interim Chief Financial Officer, effective May 29, 2026, citing more than twenty years of finance and accounting experience across multiple healthcare businesses.
How This Changes the Fair Value For LENSAR
-
Fair value remains at US$8.50, with no change in the updated model.
-
Projected revenue growth is adjusted from 26.22% to 19.62%.
-
Expected net profit margin is updated from 8.51% to 12.19%.
-
Assumed future P/E multiple moves from 13.87x to 10.56x.
-
The discount rate is revised from 7.86% to 7.61%.
Never Miss an Update: Follow The Narrative
Narratives link LENSAR's business story to a set of assumptions about growth, profitability, and fair value, and they update as new information comes through. Following a narrative helps you see how changing fundamentals and risks feed into the price targets you read about.
Head over to the Simply Wall St Community and follow the Narrative on LENSAR to stay up to date on:
-
How ALLY System placements, procedure volumes, and contracts in markets such as Europe and Southeast Asia relate to revenue potential and operating room productivity.
-
The focus on converting femto naive and competing system users to ALLY, and what that could mean for recurring revenues as more systems reach full procedure capacity.
-
Key execution risks, including reliance on distributor effectiveness, competition from larger ophthalmic companies, and earnings volatility linked to items such as warrant liabilities.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include LNSR .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
